Mastocytosis pp 115-122 | Cite as

Gastrointestinal Manifestations of Systemic Mastocytosis

  • Matthew J. HamiltonEmail author


Gastrointestinal involvement is common in patients with systemic mastocytosis, and it is important to be able to recognize and characterize the various GI symptoms that these patients often experience. Through a systematic approach to the history taking, physical exam, and diagnostic testing, GI symptoms in systemic mastocytosis can be attributed to mast cell activation, mast cell infiltration, or other primary GI disorders or diseases unrelated to the mastocytosis. Following this approach, specific treatments can be tried or titrated to reach the desired effect of relief of symptoms and prevention of complications.


Mastocytosis Gastrointestinal Tryptase Cromolyn Endoscopy Colonoscopy Motility Malabsorption Portal hypertension 


  1. 1.
    Castells M, Austen KF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol. 2002;127:147–52.CrossRefGoogle Scholar
  2. 2.
    Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am. 2000;14:579–623.CrossRefGoogle Scholar
  3. 3.
    Sokol H, Georgin-Lavialle S, Canioni D, Barete S, Damaj G, et al. Gastrointestinal manifestations in mastocytosis: a study of 83 patients. J Allergy Clin Immunol. 2013;132:866–73 e1-3.CrossRefGoogle Scholar
  4. 4.
    Douaiher J, Succar J, Lancerotto L, Gurish MF, Orgill DP, et al. Development of mast cells and importance of their tryptase and chymase serine proteases in inflammation and wound healing. Adv Immunol. 2014;122:211–52.CrossRefGoogle Scholar
  5. 5.
    Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat Rev Immunol. 2006;6:218–30.CrossRefGoogle Scholar
  6. 6.
    Doyle LA, Sepehr GJ, Hamilton MJ, Akin C, Castells MC, Hornick JL. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol. 2014;38:832–43.CrossRefGoogle Scholar
  7. 7.
    Hahn HP, Hornick JL. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis. Am J Surg Pathol. 2007;31:1669–76.CrossRefGoogle Scholar
  8. 8.
    Akin C. Mast cell activation syndromes. J Allergy Clin Immunol. 2017;140:349–55.CrossRefGoogle Scholar
  9. 9.
    Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol. 1990;85:852–5.CrossRefGoogle Scholar
  10. 10.
    Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med. 2004;350:735–6.CrossRefGoogle Scholar
  11. 11.
    Povoa P, Ducla-Soares J, Fernandes A, Palma-Carlos AG. A case of systemic mastocytosis; therapeutic efficacy of ketotifen. J Intern Med. 1991;229:475–7.CrossRefGoogle Scholar
  12. 12.
    Ustun C, DeRemer DL, Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res. 2011;35:1143–52.CrossRefGoogle Scholar
  13. 13.
    Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013;15(Suppl 3):S5.CrossRefGoogle Scholar
  14. 14.
    Hodges K, Kennedy L, Meng F, Alpini G, Francis H. Mast cells, disease and gastrointestinal cancer: a comprehensive review of recent findings. Transl Gastrointest Cancer. 2012;1:138–50.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Mastocytosis CenterBrigham and Women’s HospitalBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA

Personalised recommendations